Oral Cicaglocal Enhances Wound Healing After Mohs Surgery
A recent double-blind, placebo-controlled clinical trial published in the Journal of Cosmetic Dermatology evaluated the efficacy of oral Cicaglocal in improving postoperative healing following Mohs micrographic surgery for facial skin cancer. The supplement combines bromelain, Centella asiatica, hyaluronic acid, vitamins, and minerals.
Study Overview:
- Participants: 24 patients between 50 and 80 years old, undergoing Mohs surgery for basal or squamous cell carcinoma, were randomly assigned to receive either Cicaglocal or a placebo postoperatively.
- Assessment Timeline: Wound healing was evaluated at 7 and 14 days after surgery using objective measures such as erythema levels, the Early Healing Score (EHS), and subjective satisfaction ratings from both patients and clinicians.
- Results: The Cicaglocal group demonstrated faster resolution of redness, higher healing scores, quicker full recovery, and greater satisfaction across both patient and provider ratings.
How It Works: Cicaglocal’s ingredients target multiple healing pathways:
- Bromelain – Supports debridement and reduces inflammation
- Centella asiatica – Promotes collagen production and vascular support
- Hyaluronic acid – Encourages granulation tissue formation and skin hydration
- Vitamins & Minerals – Enhance immune response and cellular regeneration
Clinical Relevance: Cicaglocal may be a valuable adjunct for accelerating recovery after dermatologic procedures—especially in older patients or those with healing impairments. Its oral delivery and natural compound profile make it a practical option for routine use.
Keywords:
Cicaglocal,
Mohs surgery,
bromelain,
Centella asiatica,
hyaluronic acid